Lyra Therapeutics (LYRA) Projected to Post Earnings on Thursday

Lyra Therapeutics (NASDAQ:LYRA) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Lyra Therapeutics to post earnings of ($1.24) per share and revenue of $0.44 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Lyra Therapeutics Stock Up 1.7%

Shares of LYRA opened at $1.30 on Tuesday. The stock’s fifty day simple moving average is $1.96 and its 200-day simple moving average is $4.26. The firm has a market capitalization of $2.30 million, a PE ratio of -0.06 and a beta of 0.01. Lyra Therapeutics has a 12-month low of $0.91 and a 12-month high of $37.50.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lyra Therapeutics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and an average target price of $100.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new stake in shares of Lyra Therapeutics during the third quarter worth $128,000. DRW Securities LLC acquired a new position in Lyra Therapeutics in the fourth quarter valued at about $52,000. Finally, Bank of America Corp DE boosted its holdings in Lyra Therapeutics by 33.7% during the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock worth $256,000 after buying an additional 7,190 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).